@Biostock The Dep Docetaxal Ph1 trial commenced in January 2014, 8.5 years ago and commenced the Ph 2 in September 2017 so it took almost 4 years to recruit 30 patients and run the trial, all in Australia. The alarm bells should have started ringing then however when they decided to shift the Ph 2 to the UK in order to expedite recruitment it appeared on the surface to be a smart move. At the time it was announced that because of the shift in trial site the trial would run for 2years.
That was 5 years ago.
8.5 years and Ph 2 is still running with no endpoint in sight.
I no longer believe any of the statements coming from our overpaid CEO who perhaps would have been better suited in life writing fiction novels.
ASCO - but where is SPL clinical data?, page-2
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.003(3.09%) |
Mkt cap ! $41.73M | |||
| Open | High | Low | Value | Volume |
| 9.9¢ | 10.5¢ | 9.9¢ | $12.72K | 127.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 50204 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 69981 | 3 |
View Market Depth
| Last trade - 10.43am 18/09/2024 (20 minute delay) ? |
| SPL (ASX) Chart |